<DOC>
	<DOC>NCT01695200</DOC>
	<brief_summary>This is a 12-week open label trial to evaluate whether omega-3 fatty acids is effective in reducing the severity of autism and its comorbidities.</brief_summary>
	<brief_title>Omega-3 Fatty Acids in Autism Spectrum Disorders</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Autistic Disorder</mesh_term>
	<mesh_term>Autism Spectrum Disorder</mesh_term>
	<mesh_term>Child Development Disorders, Pervasive</mesh_term>
	<criteria>Between ages 5 and 18 years old Diagnosed to have Autism, Asperger Syndrome, or PDDNOS by the DSMIV criteria; met the Autism or Spectrum classification for Autism Diagnostic Interview Revised (ADIR) and Autism Diagnostic Observation Schedule (ADOS) Written parental consent for participation Those not on current standardofcare treatments for ASD Below 5 and above 18 years old No formal diagnosis of Autism, Asperger Syndrome or PDDNOS Without written parental consent for participation Those with brain pathology such as serious head injury, epilepsy, etc. Those on current standardofcare treatment for ASD Those with psychotic symptoms, selfinjurious behaviours and/or suicidal tendency, and other history of clinically significant medical conditions screened by the attending doctor to have increase the risk associated with study participation Those on other types of medication or supplements or with change in dose</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>April 2013</verification_date>
</DOC>